Correction to: Nature Medicine https://doi.org/10.1038/s41591-025-03738-z, published online 31 May 2025.
In the version of the article initially published, in the final sentence of the “Primary endpoint” paragraph, “72.2% for Arm C (N = 193)” should have read “72.2% for Arm C (N = 194)”. In the “OS” paragraph, “one-sided P = 0.6791; Fig. 4b” should have read “one-sided P = 0.6043; Fig. 4b”. In the first sentence of the “Safety” paragraph, “Arm B (N = 349)” should have read “Arm B (N = 348)”. In the “Stratified hazard ratio (95%CI)” column of Fig. 4b, “(0.64–1.88)” should have read “(0.64–1.79)”. In the Table 2 legend, “Included are TRAEs that occurred in at least 5% of the patients…” should have read “Included are TRAEs that occurred in at least 7.5% of the patients…”. In Extended Data Figs. 1 and 2, “Stratified hazard ratio” should have read “Unstratified hazard ratio”. These corrections have now been made to the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Shore, N.D., Powles, T.B., Bedke, J. et al. Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med 31, 2815 (2025). https://doi.org/10.1038/s41591-025-03894-2
Published:
Issue date:
DOI: https://doi.org/10.1038/s41591-025-03894-2
